Omeprazole

A comprehensive review

F. Massoomi, J. Savage, Christopher J. Destache

Research output: Contribution to journalReview article

64 Citations (Scopus)

Abstract

Omeprazole is a member of a new class of substituted benzimidazoles. These agents inhibit the proton pump in the gastric parietal cell, blocking the final step in the gastric acid secretory pathway. Omeprazole has been investigated for the treatment of gastric ulcer, duodenal ulcer, gastroesophageal reflux, and various hypersecretory states. The prolonged inhibition of gastric acid secretion allows for once-daily dosing in patients with peptic ulcer disease and gastroesophageal reflux, and once- or twice- daily dosing in patients with Zollinger-Ellison syndrome. Compared with currently available therapies, omeprazole is well tolerated and demonstrates a more rapid ulcer healing rate. It is superior to conventional therapies in the treatment of Zollinger-Ellison syndrome. Side effects are infrequent when the drug is used for the short-term management of ulcers.

Original languageEnglish
Pages (from-to)46-59
Number of pages14
JournalPharmacotherapy
Volume13
Issue number1
StatePublished - 1993

Fingerprint

Omeprazole
Zollinger-Ellison Syndrome
Gastric Acid
Gastroesophageal Reflux
Ulcer
Gastric Parietal Cells
Benzimidazoles
Proton Pumps
Secretory Pathway
Stomach Ulcer
Therapeutics
Duodenal Ulcer
Peptic Ulcer
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Massoomi, F., Savage, J., & Destache, C. J. (1993). Omeprazole: A comprehensive review. Pharmacotherapy, 13(1), 46-59.

Omeprazole : A comprehensive review. / Massoomi, F.; Savage, J.; Destache, Christopher J.

In: Pharmacotherapy, Vol. 13, No. 1, 1993, p. 46-59.

Research output: Contribution to journalReview article

Massoomi, F, Savage, J & Destache, CJ 1993, 'Omeprazole: A comprehensive review', Pharmacotherapy, vol. 13, no. 1, pp. 46-59.
Massoomi F, Savage J, Destache CJ. Omeprazole: A comprehensive review. Pharmacotherapy. 1993;13(1):46-59.
Massoomi, F. ; Savage, J. ; Destache, Christopher J. / Omeprazole : A comprehensive review. In: Pharmacotherapy. 1993 ; Vol. 13, No. 1. pp. 46-59.
@article{a703595331b245f9a3eb4292472cbee9,
title = "Omeprazole: A comprehensive review",
abstract = "Omeprazole is a member of a new class of substituted benzimidazoles. These agents inhibit the proton pump in the gastric parietal cell, blocking the final step in the gastric acid secretory pathway. Omeprazole has been investigated for the treatment of gastric ulcer, duodenal ulcer, gastroesophageal reflux, and various hypersecretory states. The prolonged inhibition of gastric acid secretion allows for once-daily dosing in patients with peptic ulcer disease and gastroesophageal reflux, and once- or twice- daily dosing in patients with Zollinger-Ellison syndrome. Compared with currently available therapies, omeprazole is well tolerated and demonstrates a more rapid ulcer healing rate. It is superior to conventional therapies in the treatment of Zollinger-Ellison syndrome. Side effects are infrequent when the drug is used for the short-term management of ulcers.",
author = "F. Massoomi and J. Savage and Destache, {Christopher J.}",
year = "1993",
language = "English",
volume = "13",
pages = "46--59",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Omeprazole

T2 - A comprehensive review

AU - Massoomi, F.

AU - Savage, J.

AU - Destache, Christopher J.

PY - 1993

Y1 - 1993

N2 - Omeprazole is a member of a new class of substituted benzimidazoles. These agents inhibit the proton pump in the gastric parietal cell, blocking the final step in the gastric acid secretory pathway. Omeprazole has been investigated for the treatment of gastric ulcer, duodenal ulcer, gastroesophageal reflux, and various hypersecretory states. The prolonged inhibition of gastric acid secretion allows for once-daily dosing in patients with peptic ulcer disease and gastroesophageal reflux, and once- or twice- daily dosing in patients with Zollinger-Ellison syndrome. Compared with currently available therapies, omeprazole is well tolerated and demonstrates a more rapid ulcer healing rate. It is superior to conventional therapies in the treatment of Zollinger-Ellison syndrome. Side effects are infrequent when the drug is used for the short-term management of ulcers.

AB - Omeprazole is a member of a new class of substituted benzimidazoles. These agents inhibit the proton pump in the gastric parietal cell, blocking the final step in the gastric acid secretory pathway. Omeprazole has been investigated for the treatment of gastric ulcer, duodenal ulcer, gastroesophageal reflux, and various hypersecretory states. The prolonged inhibition of gastric acid secretion allows for once-daily dosing in patients with peptic ulcer disease and gastroesophageal reflux, and once- or twice- daily dosing in patients with Zollinger-Ellison syndrome. Compared with currently available therapies, omeprazole is well tolerated and demonstrates a more rapid ulcer healing rate. It is superior to conventional therapies in the treatment of Zollinger-Ellison syndrome. Side effects are infrequent when the drug is used for the short-term management of ulcers.

UR - http://www.scopus.com/inward/record.url?scp=0027453237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027453237&partnerID=8YFLogxK

M3 - Review article

VL - 13

SP - 46

EP - 59

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1

ER -